Belite Bio (BLTE) Competitors

Roivant Sciences (NASDAQ:ROIV) and Belite Bio (NASDAQ:BLTE) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, community ranking, earnings, institutional ownership, media sentiment and dividends.

Is ROIV or BLTE more profitable?

Belite Bio has a net margin of 0.00% compared to Roivant Sciences' net margin of -119.54%. Roivant Sciences' return on equity of -14.05% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-119.54%	-14.05%	-12.81%
Belite Bio	N/A	-31.94%	-30.73%

Which has more volatility & risk, ROIV or BLTE?

Roivant Sciences has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500. Comparatively, Belite Bio has a beta of -1.52, suggesting that its share price is 252% less volatile than the S&P 500.

Do insiders & institutionals believe in ROIV or BLTE?

64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 0.5% of Belite Bio shares are held by institutional investors. 7.9% of Roivant Sciences shares are held by insiders. Comparatively, 13.3% of Belite Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Do analysts rate ROIV or BLTE?

Roivant Sciences presently has a consensus price target of $17.50, suggesting a potential upside of 62.94%. Belite Bio has a consensus price target of $96.67, suggesting a potential upside of 64.40%. Given Belite Bio's higher probable upside, analysts plainly believe Belite Bio is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.00
Belite Bio	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has higher valuation and earnings, ROIV or BLTE?

Roivant Sciences has higher revenue and earnings than Belite Bio. Roivant Sciences is trading at a lower price-to-earnings ratio than Belite Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$122.59M	62.52	$4.35B	-$0.15	-71.60
Belite Bio	N/A	N/A	-$31.63M	-$1.18	-49.83

Does the MarketBeat Community prefer ROIV or BLTE?

Roivant Sciences received 21 more outperform votes than Belite Bio when rated by MarketBeat users. However, 97.14% of users gave Belite Bio an outperform vote while only 78.57% of users gave Roivant Sciences an outperform vote.

Company	Underperform	Outperform
Roivant Sciences	Outperform Votes 55 78.57%	Underperform Votes 15 21.43%
Belite Bio	Outperform Votes 34 97.14%	Underperform Votes 1 2.86%

Does the media refer more to ROIV or BLTE?

In the previous week, Roivant Sciences had 12 more articles in the media than Belite Bio. MarketBeat recorded 17 mentions for Roivant Sciences and 5 mentions for Belite Bio. Roivant Sciences' average media sentiment score of 0.80 beat Belite Bio's score of 0.07 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	6 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Belite Bio	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Roivant Sciences beats Belite Bio on 11 of the 17 factors compared between the two stocks.